102 related articles for article (PubMed ID: 14732836)
1. [EGF receptors in urological cancer. Molecular basis and therapeutic involvements].
Paule B; Brion N
Ann Med Interne (Paris); 2003 Nov; 154(7):448-56. PubMed ID: 14732836
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor biology (IMC-C225).
Kim ES; Khuri FR; Herbst RS
Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.
Fozing T; Scheuer C; Samnick S
Eur J Med Chem; 2010 Sep; 45(9):3780-6. PubMed ID: 20538380
[TBL] [Abstract][Full Text] [Related]
5. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
Rubin Grandis J; Chakraborty A; Melhem MF; Zeng Q; Tweardy DJ
Oncogene; 1997 Jul; 15(4):409-16. PubMed ID: 9242377
[TBL] [Abstract][Full Text] [Related]
8. Transactivation of epidermal growth factor receptor after heparin-binding epidermal growth factor-like growth factor shedding in the migration of prostate cancer cells promoted by bombesin.
Madarame J; Higashiyama S; Kiyota H; Madachi A; Toki F; Shimomura T; Tani N; Oishi Y; Matsuura N
Prostate; 2003 Nov; 57(3):187-95. PubMed ID: 14518027
[TBL] [Abstract][Full Text] [Related]
9. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.
Zimmermann M; Zouhair A; Azria D; Ozsahin M
Radiat Oncol; 2006 May; 1():11. PubMed ID: 16722544
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
[TBL] [Abstract][Full Text] [Related]
11. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
12. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
Janmaat ML; Giaccone G
Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
[TBL] [Abstract][Full Text] [Related]
13. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
Khalil MY; Grandis JR; Shin DM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells.
Bonner JA; Buchsbaum DJ; Rogers BE; Grizzle WE; Trummell HQ; Curiel DT; Fiveash JB; Ove R; Raisch KP
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):950-8. PubMed ID: 14967455
[TBL] [Abstract][Full Text] [Related]
15. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
Albanell J; Codony-Servat J; Rojo F; Del Campo JM; Sauleda S; Anido J; Raspall G; Giralt J; Roselló J; Nicholson RI; Mendelsohn J; Baselga J
Cancer Res; 2001 Sep; 61(17):6500-10. PubMed ID: 11522647
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.
Ciardiello F
Drugs; 2000; 60 Suppl 1():25-32; discussion 41-2. PubMed ID: 11129169
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.
Overholser JP; Prewett MC; Hooper AT; Waksal HW; Hicklin DJ
Cancer; 2000 Jul; 89(1):74-82. PubMed ID: 10897003
[TBL] [Abstract][Full Text] [Related]
19. Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Wu W; Yang Q; Fung KM; Humphreys MR; Brame LS; Cao A; Fang YT; Shih PT; Kropp BP; Lin HK
Mol Cell Endocrinol; 2014 Mar; 383(1-2):69-79. PubMed ID: 24296312
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]